EGFR and non-small cell lung carcinoma: However, treatment effectiveness in advanced stage IIIB or IV non-small cell lung cancer (NSCLC) without an EGFR-sensitizing mutation or ALK gene rearrangement has reached a plateau and it could depend on histological features, performance status (PS), age, and comorbidities.